Loading...

NCN

NCN

NUCANA PLC

(NCNA)

2024 6-K

Summary

Summary

Clinical Data Release

14 Oct '25

Nasdaq Compliance

5 Sep '25

Presentation Announcement

3 Sep '25

Q2 Financial Results

20 Aug '25

ADS Ratio Change

1 Aug '25

Warrant Cancellation

21 Jul '25

ADS Ratio Change

11 Jul '25

Nasdaq Delisting Notice

9 Jul '25

Sales Agreement Signed

30 Jun '25

Warrant Agreements Update

27 Jun '25

Nasdaq Compliance Alert

20 Jun '25

Management Changes

18 Jun '25

Annual Report Released

5 Jun '25

Financial Results Report

2 Jun '25

General Meeting Passed

23 Apr '25

Financial Results Update

20 Mar '25

General Meeting Notice

18 Mar '25

CFO Departure

10 Feb '25

Third Quarter Results

25 Nov '24

Clinical Data Release

12 Nov '24

Funding Update

30 Sep '24

New Patent Announcement

26 Sep '24

Data Presentation

16 Sep '24

Study Discontinued

29 Aug '24

Q2 Financial Results

15 Aug '24

Annual Meeting Summary

18 Jun '24

Q1 Financial Results

16 May '24

Annual Report Announcement

13 May '24

Compliance Regained

1 May '24

ADS Ratio Change

16 Apr '24

Cancer Research Presentation

9 Apr '24

ADS Ratio Change

27 Mar '24

Financial Results Update

20 Mar '24

External Links:

SEC

On August 29, 2024, NuCana plc announced the discontinuation of the NuTide:323 study based on an initial analysis indicating that the tested treatment was unlikely to outperform the control arm in Progression Free Survival. The safety profile was favorable, with only 12 out of 175 patients discontinuing treatment due to adverse events.

AI Assistant

NUCANA PLC

2024

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.